Healthcare Industry News: radiosurgery
News Release - August 31, 2010
Swiss Breast Cancer Patient Becomes First in World to Receive Treatment Using Gated RapidArc from Varian Medical SystemsBELLINZONA, Switzerland, Aug. 31 -- (Healthcare Sales & Marketing Network) -- A 51-year-old breast cancer patient from Switzerland has become the first person in the world to be treated using Gated RapidArc®, which makes it possible to monitor patient breathing and compensate for tumor motion while quickly delivering radiotherapy during a continuous rotation around the patient.
This development from Varian Medical Systems (NYSE:VAR ) enables the use of RapidArc radiotherapy technology in combination with respiratory gating – a process of turning the beam on and off in synchrony with the patient's breathing. This technique increases the precision of treatment delivery by compensating for tumor motion.
The treatment took place at the Istituto Oncologico della Svizzera Italiana (IOSI) radiation oncology unit in Bellinzona, a public comprehensive cancer center serving 330,000 inhabitants in southern Switzerland, and part of Ente Ospedaliero Cantonale at San Giovanni Hospital.
Dr. Giorgia Nicolini, medical physicist at IOSI, said, "This is a very fast and straightforward procedure for the patient, who doesn't speak the local language, Italian, but in any case has found it very easy to follow instructions for gating. She has been fully co-operative and the part of the treatment time taken up by breathing management is decreasing after the first sessions. She also appreciates having to spend less time on the treatment couch."
The hospital has used breath-hold gating as part of the treatment procedure for all left breast cancer patients since 2005 to better spare the heart and lung from exposure during radiotherapy treatment. Prior to Gated RapidArc, conventional seven-field gated IMRT treatments would have taken 15 minutes to deliver. Using two-arc Gated RapidArc, the treatment is concluded in around four minutes.
Dr. Nicolini said clinicians at IOSI compared RapidArc and IMRT treatment plans for the patient and decided RapidArc offered the better opportunity to spare nearby organs from exposure and target the tumor.
"The use of two partial arcs enables us to shape a better dose distribution and do a better job of sparing the opposite breast," said Antonella Richetti, M.D., head of the IOSI Radiation Oncology Department. In addition, RapidArc enabled the dose to be delivered using fewer than half the dose monitor units needed for an equivalent conventional seven-field IMRT treatment.
"We are now using Gated RapidArc to treat all left-sided breast cancer patients when there is a need to include the supraclavicolar and/or internal mammary chain lymph nodes, or when chest wall anatomy will affect the dose to organs we want to protect," said Dr. Nicolini. "We are also planning to use the technique for lung and other thoracic and abdominal tumors when suitable."
Gated RapidArc is a standard feature on the new TrueBeam™ system and is available as an option or upgrade on the Trilogy® and Clinac® iX accelerators from Varian.
Varian's RapidArc capability is now installed in more than 500 clinics around the world and the company has recorded more than 1,000 orders for the product since introducing it in 2008. Gated RapidArc, which was introduced earlier this year, is the next generation version of this clinical tool. As a result of being able to deliver IMRT treatments much more quickly than conventional fixed beam IMRT, RapidArc has the potential to enhance treatment precision and patient comfort while significantly lowering the cost per treatment.
According to breast cancer charities, one in ten of all new cancers diagnosed worldwide each year is breast cancer. It is the most common cancer in women in both developing and developed areas and is the principal cause of death from cancer among women. The World Health organization says nearly 1.4 million women worldwide were diagnosed with the disease in 2008.
Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsVarian and Tata Trusts Sign Framework Agreement for Advanced Cancer Care Solutions to Address Growing Need in India
Varian Installs Gantry for ProBeam Compact Proton Therapy System at New Treatment Center in Singapore
First Cancer Patients in Taiwan Treated with Varian HyperArc High-Definition Radiotherapy